Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01502878
Other study ID # HUCHT101060080
Secondary ID IAS11
Status Completed
Phase N/A
First received May 27, 2011
Last updated September 12, 2016
Start date May 2011
Est. completion date March 2016

Study information

Verified date September 2016
Source Helsinki University Central Hospital
Contact n/a
Is FDA regulated No
Health authority Finland: Ethics CommitteeFinland: Ministry of Social Affairs and Health
Study type Interventional

Clinical Trial Summary

Nut sensitization in skin prick tests is common in areas, including Finland, where birch pollen is abundant. However, sensitization to nuts in skin prick test does not predict the possibility of allergic symptoms when nuts are ingested. In this study the investigators launch and perform double-blind placebo-controlled nut challenges and oral desensitization/ protocol to those with serious symptoms in the challenge. The efficacy and safety of the new oral desensitization program is the primary outcome. The effect of oral desensitization on bronchial hyperreactivity, eosinophilic airway inflammation, and quality of life are secondary outcomes.


Description:

The investigators aim to improve nut allergy diagnosis by launching a new double-blind placebo-controlled nut (peanut, hazel nut, cashew) challenge protocol. The investigators also launch a specific oral tolerance induction (SOTI) protocol to nuts in serious nut allergy. This study takes place in the Helsinki University Skin and Allergy Hospital between May 2011 and December 2015. Inclusion criteria: age 6 to 18 years and suspected nut allergy (unclear anaphylaxis possibly caused by nuts, skin prick test to nuts ≥ 10 mm or specific-IgE ≥ 20 kU/L and have never eaten nuts, or avoids nuts and does not dare try nuts at home). Patients having uncontrolled asthma or other lung disease, having cardiovascular disease or other systemic disease, using beta-blockers, and having poor compliance, are excluded. Methods:The investigators perform skin prick tests to peanut, tree nuts and seeds, take a blood sample before the double-blind placebo-controlled food challenges (DBPCFC), and measure total IgE and specific-IgE to birch, peanut, hazel nut, allergen components Ara h 1, 2, 3, and 8, and Cor a 1 and 8. Then the serum samples are kept frozen for further component and immunologic analyses. The investigators put iv before the challenge. In DBPCFC the patients receive 5 mg, 50 mg, 200mg, and 1000mg nut protein mixt with placebo, or placebo every 30 minutes. The severity of the allergic reaction is estimated using a modified severity scale. The probability of severe/moderate reaction at low (<0.7 kU/L) and at increased (>0.7 kU/L) Ara h 2 and 8 concentrations is the primary end-point in the DBPCFC. The investigators also correlate the concentrations of Ara h 2 with the severity score. Patients with moderate or severe reaction in the challenge will be offered desensitization therapy "SOTI" using(pea)nut flour mixed with milk-free margarine. The first dose of 0.1 mg nut protein is given at hospital part of the up-dosing is made at home every 2 weeks. The patient takes an antihistamine 1 hour before each daily dose. An epinephrine autoinjector and prednisolone tablets are also prescribed for emergency use. The desensitization protocol takes 28 weeks and is personalized when needed. Exercise is avoided 1 hour following each dose. Before and after the SOTI the investigators measure food related quality of life using standardized questionnaires, and perform metacholine challenge and measure exhaled nitric oxid. After the SOTI the investigators take blood samples and perform DBPCFC again.


Recruitment information / eligibility

Status Completed
Enrollment 102
Est. completion date March 2016
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 3 Years to 18 Years
Eligibility Inclusion Criteria:

- sensitization in skin prick test or in serum nut-specific IgE

- unknown anaphylaxis suspected caused by nuts

- never eaten nuts

- if challenge positive with serious symptoms, OIT

Exclusion Criteria:

- active asthma and low lung function,

- pregnancy, cardiovascular or other disease that might worsen during the challenge and OIT

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Nut challenge
Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
Nut challenge: Placebo
Dried banana mixed with oat yoghurt or chocolate pudding
Nut oral desensitization
Roasted peanut powder mixed with milk- and soy-free margarine

Locations

Country Name City State
Finland Helsinki University Central Hospital, Skin and Allergy Hospital Helsinki
Finland Helsinki University Central Hospital, Skin and Allergy Hospital Helsinki

Sponsors (1)

Lead Sponsor Collaborator
Helsinki University Central Hospital

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of nut oral desensitization Change from baseline in the amount of nut (mg) tolerated in a double-blind placebo-controlled oral challenge at 1 month after the 6-month oral desensitization therapy. 7 months No
Secondary Effect of the treatment on quality of life Change from baseline in Quality of life questionnaire square before and after the oral desensitization therapy 7 months No
Secondary Effect of the treatment on bronchial hyperreactivity and airway inflammation Change from baseline in bronchial hyperreactivity in metacholine challenge and in eosinophilic airway inflammation measured by multiple channel exhaled nitric oxid 1 year Yes
Secondary Safety of nut oral desensitization therapy Number of participants with adverse events as a measure of safety and tolerability 7 months Yes
Secondary Effect of the treatment on eosinophilic airway inflammation Change from baseline in exhaled nitric oxid concentration 1 year Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05667610 - Immune-supportive Diet and Gut Permeability in Allergic Children N/A
Active, not recruiting NCT04801823 - The TreEat Study- Can Early Introduction of Tree Nuts Prevent Tree Nut Allergy in Infants With Peanut Allergy Phase 3
Recruiting NCT03309488 - Basophil Activation Test to Diagnose Food Allergy
Recruiting NCT05309772 - The Clinical Impact of the Basophil Activation Test to Diagnose Food Allergy N/A
Completed NCT02966938 - Visual Recognition of Allergens by Allergic Patients and/or Their Parents N/A